Executive Summary

Dose As directed by the

Formulation Montelukast
physician

Asthma
Total Market- Direct 35.07 Cr @ Allergic rhinitis
Market Indication
25.07 % Hay Fever
EIB
Rs. 100/5mg 7 Tablet
Doctor Segment GP, Paediatrician, Pulmonologist MRP
Rs. 268/10 mg Tablet
Formulation & Strength
• Montelukast sodium, the active ingredient in SINGULAIR, is a selective and orally
active leukotriene receptor antagonist.
Variant Dosage Target Patient
Singulair Oral 4mg 6-23 months
Granules
Singulair Chewable 4mg 2-5 years old
tablet/ Oral
Granules

Singulair Chewable 5mg 6-14 years old

tablet
Singulair tablet 10mg >15 years old
Respiratory Market Overview

Year 2014 2015 2016 2017 2018

Value (Cr’s) 5823 6577 7833 8329 9015

% GR 15.2 12.6 9.4 6.3 6.6

Monteleukast solid was valued at 35 crs @ 25% growth .

Ref: AIOCD AWACS,

IMS HEALTH MARKET REFLECTION REPORT
JUN16
PRODUCT AND COMPETITOR ANALYSIS

Rs '000 Sales Promotion Sales

Current MAT 2016 Level Force

Singulair- MSD Pharma 82111.378 M 350

Emlukast FX - Dr. Reddy's Labs 47088.235 M 400

Montair–Cipla 329875.927 M 600

Romilast– Ranbaxy 94832.241 M 550

Telekast - Lupin Ltd 86079.526 M 400

 Indication
Ashama
Exercise Allergic with
Allergic Hay induced skin allergic
Asthma Rhinitis Fever bronchospasm conditions rhinitis
Singulair- MSD
Pharma + + + + +
Emlukast FX - Dr.
Reddy's Labs + + + + +

Montair–Cipla + + + + +

Romilast– Ranbaxy + + +

Telekast - Lupin Ltd + + + +

 Customer Analysis
Customers Ranked By Size (#) Influencer Who Contacts
Promotional Priority (Yes, No)

GPs 40000 Yes MR

Specialists 25000 Yes MR, RBM

Hospital HCPs 20000 Yes MR

Key Opinion Leaders 750 Yes MR,ABM